Muscle, Recovery & Performance

Two Halves of One Axis

The GH axis is studied through two complementary compound types:

• GHRH analogues (CJC-1295, Tesamorelin) amplify the magnitude of GH pulses. CJC-1295's drug affinity complex extends its half-life from minutes to roughly 6-8 days. Tesamorelin has the most extensive peer-reviewed clinical data of any GHRH analogue, including published Phase III work on visceral adipose tissue.
• GHRPs (Ipamorelin) trigger pulsatile release through the ghrelin receptor. Ipamorelin's selectivity for GH release without meaningful cortisol or prolactin elevation is why it appears in most modern research blends.

Because the two act on separate receptors, they are frequently studied together, which is why the 2X and 4X blends exist.

Downstream Signalling

IGF-1 LR3 is a modified IGF-1 analogue with reduced binding-protein affinity and a half-life of roughly 20-30 hours versus about 15 minutes for native IGF-1. Research focuses on mTOR signalling, satellite cell activation, and protein synthesis. MGF, included in the 4X blend, is an IGF-1 splice variant that responds to mechanical stress and is studied for localised hypertrophy signalling.

Documented Research Areas

Muscle protein synthesis, fat oxidation and body composition, sleep architecture and recovery quality, and IGF-1 axis modulation. Administration timing in published protocols clusters around low-insulin windows: fasted, or before sleep, when natural GH pulses occur.

Research use only. Not approved for human therapeutic use.